<?xml version="1.0" encoding="utf8"?>
 <!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN" "http://jats.nlm.nih.gov/publishing/1.0/JATS-journalpublishing1.dtd"> <article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="in-brief" dtd-version="1.0" xml:lang="en">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">JCDP</journal-id>
      <journal-title-group>
        <journal-title>Journal of Clinical and Diagnostic Pathology</journal-title>
      </journal-title-group>
      <issn pub-type="epub">2689-5773</issn>
      <publisher>
        <publisher-name>Open Access Pub</publisher-name>
        <publisher-loc>United States</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id">JCDP-19-2890</article-id>
      <article-id pub-id-type="doi">10.14302/issn.2689-5773.jcdp-19-2890</article-id>
      <article-categories>
        <subj-group>
          <subject>in-brief</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Transmutation of Sweat Glands - Eccrine Porocarcinoma</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Anubha</surname>
            <given-names>Bajaj</given-names>
          </name>
          <xref ref-type="aff" rid="idm1849817492">1</xref>
          <xref ref-type="aff" rid="idm1849815332">*</xref>
        </contrib>
      </contrib-group>
      <aff id="idm1849817492">
        <label>1</label>
        <addr-line>MD. (Pathology) Panjab University, Department of Histopathology, A.B. iagnostics, A-1, Ring Road, Rajouri Garden, New Delhi, 110027, India.</addr-line>
      </aff>
      <aff id="idm1849815332">
        <label>*</label>
        <addr-line>corresponding author</addr-line>
      </aff>
      <contrib-group>
        <contrib contrib-type="editor">
          <name>
            <surname>Qiping</surname>
            <given-names>Dong</given-names>
          </name>
          <xref ref-type="aff" rid="idm1849817492">1</xref>
        </contrib>
      </contrib-group>
      <author-notes>
        <corresp>Corresponding author: Anubha Bajaj, MD (Pathology), Panjab University; Department of Histopathology, A.B. Diagnostics, A-1, Ring Road, Rajouri Garden, New Delhi 110027, India. Email: <email>anubha.bajaj@yahoo.com</email></corresp>
        <fn fn-type="conflict" id="idm1842661772">
          <p>The authors have declared that no competing interests exist.</p>
        </fn>
      </author-notes>
      <pub-date pub-type="epub" iso-8601-date="2019-07-01">
        <day>01</day>
        <month>07</month>
        <year>2019</year>
      </pub-date>
      <volume>1</volume>
      <issue>1</issue>
      <fpage>19</fpage>
      <lpage>27</lpage>
      <history>
        <date date-type="received">
          <day>22</day>
          <month>05</month>
          <year>2019</year>
        </date>
        <date date-type="accepted">
          <day>28</day>
          <month>06</month>
          <year>2019</year>
        </date>
        <date date-type="online">
          <day>01</day>
          <month>07</month>
          <year>2019</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>© </copyright-statement>
        <copyright-year>2019</copyright-year>
        <copyright-holder>Anubha Bajaj</copyright-holder>
        <license xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">
          <license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
        </license>
      </permissions>
      <self-uri xlink:href="http://openaccesspub.org/jcdp/article/1118">This article is available from http://openaccesspub.org/jcdp/article/1118</self-uri>
      <abstract>
        <p>Initially described by Pinkus and Mehregan in 1963 as an  epidermotropic eccrine carcinoma,<bold> </bold>eccrine        porocarcinoma cogitates an exceptional sweat gland malignancy. Eccrine porocarcinoma was adapted as a                        nomenclature by Mishisma and Morikoin in 1969. The neoplasm is a malignant analogue of eccrine poroma which is a benign tumour of intra-dermal sweat glands. Eccrine porocarcinoma  is an invasive malignancy of eccrine sweat gland with an acrosyringial genesis. Nomenclature includes epidermotropic eccrine carcinoma, eccrine                                         poroepithelioma, malignant  hidroacanthoma simplex, malignant intra-epidermal eccrine poroma, malignant eccrine poroma, malignant syringoacanthoma and dysplastic poroma (1,2). Sweat gland carcinoma are categorized into               subgroups with the classical eccrine porocarcinoma  or  eccrine adenocarcinoma as a prevalent subcategory.                 Lesions are enlisted as         </p>
        <p>Classic type eccrine adenocarcinoma ( eccrine porocarcinoma).</p>
        <p>Syringoid eccrine carcinoma                                                                                  </p>
        <p>Microcystic adnexal carcinoma                                                                </p>
        <p>Mucinous eccrine carcinoma                                                          </p>
        <p>Muco-epidermoid carcinoma                                                                          </p>
        <p>Adenoid cystic carcinoma                                                                        </p>
        <p>Aggressive digital papillary adenoma/adenocarcinoma</p>
      </abstract>
      <kwd-group>
        <kwd>Mucinous eccrine carcinoma</kwd>
        <kwd>Adenoid cystic carcinoma  </kwd>
      </kwd-group>
      <counts>
        <fig-count count="13"/>
        <table-count count="0"/>
        <page-count count="9"/>
      </counts>
    </article-meta>
  </front>
  <body>
    <sec id="idm1849680476" sec-type="intro">
      <title>Introduction</title>
      <p>Preface  Eccrine porocarcinoma is designated as an exceptional sweat gland malignancy which was initially described by Pinkus and Mehregan in 1963 as an  epidermotropic eccrine carcinoma. Subsequently, Mishisma and Morikoin in 1969 adopted the nomenclature of “eccrine porocarcinoma”. The neoplasm is a malignant analogue of eccrine poroma which is a frequently elucidated  benign tumour of intra-dermal sweat glands. Eccrine porocarcinoma  is an invasive malignancy of eccrine sweat glands and demonstrates an acrosyringial genesis.  Additionally, the neoplasm is designated as epidermotropic eccrine carcinoma, eccrine poroepithelioma, malignant  hidroacanthoma simplex, malignant intra-epidermal eccrine poroma, malignant eccrine poroma, malignant syringoacanthoma and dysplastic poroma <xref ref-type="bibr" rid="ridm1842115508">1</xref><xref ref-type="bibr" rid="ridm1842118460">2</xref>. Sweat gland carcinomas are categorized into subgroups along  with the classical eccrine porocarcinoma  or  eccrine adenocarcinoma as a prevalent subcategory. Lesions are enlisted as</p>
      <p>Classic type eccrine adenocarcinoma (eccrine porocarcinoma).</p>
      <p>Syringoid eccrine carcinoma                                                                            </p>
      <p>Microcystic adnexal carcinoma</p>
      <p>Mucinous eccrine carcinoma</p>
      <p>Muco-epidermoid carcinoma </p>
      <p>Adenoid cystic carcinoma</p>
      <p>Aggressive digital papillary adenoma/adenocarcinoma<xref ref-type="bibr" rid="ridm1842118460">2</xref><xref ref-type="bibr" rid="ridm1842222492">3</xref></p>
      <sec id="idm1849678388">
        <title>Disease Characteristics</title>
        <p>Eccrine porocarcinoma is described as an infrequent malignant  adnexal neoplasm engendered from  intra-epidermal portion of sweat glands. The tumour has an estimated prevalence of 0.005% to 0.01% of epithelial cutaneous neoplasm. Eccrine porocarcinoma  commonly occurs in the elderly within  6<sup>th</sup> and 7<sup>th</sup> decades  and manifests  a female predominance or an equivalent gender predisposition.  Duration of lesions can vary from  2 months to 50 years.                                                                                      Porocarcinoma  frequently  appears on the lower extremity (&gt;50%), trunk (24%), head (18%)  and rarely in regions delineating a congregation of eccrine sweat glands. Torso, head and neck, abdomen, upper limbs, scalp,  breast, vulva, scrotum  and  nail bed are infrequently implicated.  Lesions of the scalp  are discerned in beneath &lt; 20% instances <xref ref-type="bibr" rid="ridm1842118460">2</xref><xref ref-type="bibr" rid="ridm1842222492">3</xref>.                                                                                                   Eccrine porocarcinoma  can emerge  as a de novo disorder  or sequential  to a preceding lesion such as eccrine poroma, nevus sebaceous, chronic lymphocytic  leukaemia  or actinic keratosis.   An estimated 20% eccrine  poromas  delineate a malignant                transformation <xref ref-type="bibr" rid="ridm1842118460">2</xref><xref ref-type="bibr" rid="ridm1842222492">3</xref>.</p>
        <p>Eccrine porocarcinoma can be concurrent to immune suppression (transplant recipients, HIV infection, chemotherapy), radiation exposure and chronic radiation dermatitis. Eccrine porocarcinoma can arise in association with extra-mammary Paget’s disease, sarcoidosis, pernicious anaemia, Hodgkin’s lymphoma, HIV infection or xeroderma pigmentosum <xref ref-type="bibr" rid="ridm1842222492">3</xref><xref ref-type="bibr" rid="ridm1841973484">4</xref>.                                                                                                 Abrupt  metamorphosis  of a benign neoplasm into a nodular, infiltrative, ulcerated or polypoid tumefaction is  indicative of malignant conversion. The exceptional  eccrine porocarcinoma exhibits a variable clinical  appearance with an absence of distinctive features. Thus, a definitive  clinical diagnosis necessitates an adequate histological  concordance. Lesions can be misdiagnosed as  squamous  cell carcinoma, basal cell carcinoma, seborrheic keratosis or metastatic adenocarcinoma.</p>
        <p>Extensive tissue sampling  of the tumefaction exhibits an infiltrative  pattern of tumour evolution with nuclear enlargement and mitotic activity. Cytological atypia and stromal infiltration can classify the lesion as a porocarcinoma <xref ref-type="bibr" rid="ridm1842118460">2</xref><xref ref-type="bibr" rid="ridm1841973484">4</xref>.                                                                                                                                                                            </p>
        <p>Expeditious tumour progression, ulcerative manifestation and multiple lesions indicate a localized  reoccurrence or metastasis to adjacent viscera such as lymph nodes, lungs, liver, urinary bladder, peritoneum or retro-peritoneum <xref ref-type="bibr" rid="ridm1841973484">4</xref><xref ref-type="bibr" rid="ridm1841969308">5</xref>.                                                                                     </p>
      </sec>
      <sec id="idm1849677020">
        <title>Clinical Elucidation</title>
        <p>An ulcerative  plaque,  nodule or a tumefaction is exemplified clinically. Frequently,  a reddish, nodular, cauliflower like excrescence   or  verrucous plaques with infiltration of adjacent tissue and an ulcerated, haemorrhagic  superimposed epidermis is discerned.   Enlarged, painless, enhancing, exophytic, reddish papules or tumefaction can  also be cogitated. Lesions can be present for long duration with a sudden augmentation in magnitude and serous discharge.  Tumours can  range from &lt; 1 centimetre  to 10 centimetres in magnitude.                                                                                                                 </p>
        <p>A non healing, nodular, haemorrhagic, ulcerated, polypoidal  lesion with an inverted perimeter and magnitude of 8 centimetres to  10 centimetres can be cogitated. A loco-regional tumour infiltration is  discerned with  recent and rapid progression <xref ref-type="bibr" rid="ridm1841973484">4</xref><xref ref-type="bibr" rid="ridm1841969308">5</xref>.                                                                      </p>
        <p>The neoplasm is devoid of regional lymph node enlargement. Surgical borders can be devoid of / or may exhibit tumour infiltration. Absence  of specific clinical attributes and appearance of benign poroid features  can engender a diagnostic dilemma <xref ref-type="bibr" rid="ridm1841969308">5</xref><xref ref-type="bibr" rid="ridm1841952812">6</xref>.                                                                                                       </p>
      </sec>
      <sec id="idm1849677308">
        <title>Histological Elucidation</title>
        <p>Malignant transformation into an eccrine porocarcinoma  from an adjacent poroma can be discerned on histology. Thus,  tissue specimens can demonstrate a cytological  uniformity, appear devoid of anaplasia and depict a benign composition.                                                                                                             Tumour perimeter can indicate the emergence of an infiltrating squamous cell carcinoma or  carcinoma of skin adnexa with squamous differentiation.                                                                                                      </p>
        <p>Eccrine porocarcinoma  is an infiltrative,  high grade tumour which is  contiguous with superimposed  epidermis, depicts  a partially lobular architecture  and a diameter usually exceeding &gt; 90 millimetres. An endophytic pattern of tumour evolution is elucidated with invasion of deep reticular dermis and subcutaneous tissue <xref ref-type="bibr" rid="ridm1841969308">5</xref><xref ref-type="bibr" rid="ridm1841952812">6</xref>.                                                                                                                                     </p>
        <p>Eccrine porocarcinoma on morphological elucidation  depicts the incrimination of cutaneous structures, foci of ulceration along with multiple areas  of cellular infiltration. Tumefaction  arises from  basal layer of skin.                                                                                                </p>
        <p>Classically,  intra-epidermal and dermal nests of tumour cells exhibiting cellular atypia and enhanced mitotic activity are enunciated. Tumour aggregates articulate well demarcated, enlarged, atypical  polygonal cells with indistinct cellular and nuclear outline, nuclear hyperchromasia , irregular nuclei, vesicular or prominent nucleoli  and minimal  eosinophilic cytoplasm.  Polygonal tumour cells can depict central keratinisation <xref ref-type="bibr" rid="ridm1841952812">6</xref><xref ref-type="bibr" rid="ridm1841949716">7</xref>.                                                                                                                                                                       </p>
        <p>The neoplasm  is composed of lobules of aberrant epithelial  cells configured  in cords with incrimination of the dermis and epidermis..  Malignant  cells  congregate  within the epidermis or infiltrate the dermis, especially  in the primary tumour. Tumour cells within  tumour aggregates display a well demarcated cellular outline and appear  distinct from encompassing squamous cells. Numerous tumour cell clusters  demonstrate a cystic lumen. Prominent epidermal  acanthosis is discerned  on account of tumour cell  proliferation <xref ref-type="bibr" rid="ridm1841952812">6</xref><xref ref-type="bibr" rid="ridm1841949716">7</xref>.                                                                                                         </p>
        <p>Granular arrangement of malignant cells and intercellular bridges are conspicuous with the demonstration of  nuclear atypia,  pleomorphism, prominent mitosis and tumour necrosis. A peripheral palisade is discernible within the cellular aggregates.  Mitotic figures  are common and can be quantified as up to  12 mitosis/ high power field. Tumour differentiation  can prominently be of the ductal category with the demonstration of intra-cytoplasmic lumina. Comedo type tumour necrosis is evident along with foci of squamous differentiation The  neoplasm is reactive to  periodic acid Schiff ‘s (PAS) stain. (<xref ref-type="fig" rid="idm1842389164">Figure 1</xref>, <xref ref-type="fig" rid="idm1842389308">Figure 2</xref>, <xref ref-type="fig" rid="idm1842329476">Figure 3</xref>, <xref ref-type="fig" rid="idm1842328540">Figure 4</xref>, <xref ref-type="fig" rid="idm1842325300">Figure 5</xref>, <xref ref-type="fig" rid="idm1842325444">Figure 6</xref>, <xref ref-type="fig" rid="idm1842324796">Figure 7</xref>, <xref ref-type="fig" rid="idm1842330916">Figure 8</xref>, <xref ref-type="fig" rid="idm1842331060">Figure 9</xref>, <xref ref-type="fig" rid="idm1842329980">Figure 10</xref>, <xref ref-type="fig" rid="idm1842309436">Figure 11</xref>, <xref ref-type="fig" rid="idm1842310588">Figure 12</xref>, <xref ref-type="fig" rid="idm1842308356">Figure 13</xref>.</p>
        <fig id="idm1842389164">
          <label>Figure 1.</label>
          <caption>
            <title> Solid aggregates of tumour cells and duct structures in eccrine porocarcinoma (14).</title>
          </caption>
          <graphic xlink:href="images/image1.jpg" mime-subtype="jpg"/>
        </fig>
        <fig id="idm1842389308">
          <label>Figure 2.</label>
          <caption>
            <title> Epidermal projections lined with atypical and malignant epithelial cells in eccrine porocarcinoma (14).</title>
          </caption>
          <graphic xlink:href="images/image2.jpg" mime-subtype="jpg"/>
        </fig>
        <fig id="idm1842329476">
          <label>Figure 3.</label>
          <caption>
            <title> Cohesive accumulations with numerous ductular articulations                    of carcinoma cells in eccrine              porocarcinoma (15).</title>
          </caption>
          <graphic xlink:href="images/image3.jpg" mime-subtype="jpg"/>
        </fig>
        <fig id="idm1842328540">
          <label>Figure 4.</label>
          <caption>
            <title> Cellular atypia, mitosis and focal necrosis in eccrine porocarcinoma(16).</title>
          </caption>
          <graphic xlink:href="images/image4.jpg" mime-subtype="jpg"/>
        </fig>
        <fig id="idm1842325300">
          <label>Figure 5.</label>
          <caption>
            <title> Sweat glandular articulations and malignant cellular aggregates with cystic spaces in eccrine porocarcinoma(17).</title>
          </caption>
          <graphic xlink:href="images/image5.jpg" mime-subtype="jpg"/>
        </fig>
        <fig id="idm1842325444">
          <label>Figure 6.</label>
          <caption>
            <title> Epidermal continuity with   aggregates of atypical, solid  and cystic  epithelial cell nests in eccrine porocarcinoma (18).</title>
          </caption>
          <graphic xlink:href="images/image6.jpg" mime-subtype="jpg"/>
        </fig>
        <fig id="idm1842324796">
          <label>Figure 7.</label>
          <caption>
            <title> Aberrant and malignant                 epithelium  with cellular proliferation and pleomorphism in eccrine                   porocarcinoma with frequent mitosis(19).</title>
          </caption>
          <graphic xlink:href="images/image7.jpg" mime-subtype="jpg"/>
        </fig>
        <fig id="idm1842330916">
          <label>Figure 8.</label>
          <caption>
            <title> Disseminated  atypical  epithelial cells with cellular and nuclear                          pleomorphism, hyperchromasia, indistinct cytoplasm, vesicular nucleoli   and central keratinization in eccrine porocarcinoma(20).</title>
          </caption>
          <graphic xlink:href="images/image8.jpg" mime-subtype="jpg"/>
        </fig>
        <fig id="idm1842331060">
          <label>Figure 9.</label>
          <caption>
            <title> Branches and cords of                  malignant epithelial cells in eccrine porocarcinoma with a superficial,                 abutting  epithelium  and mitotic figures(21).</title>
          </caption>
          <graphic xlink:href="images/image9.jpg" mime-subtype="jpg"/>
        </fig>
        <fig id="idm1842329980">
          <label>Figure 10.</label>
          <caption>
            <title> Duct like configurations and  atypical epithelial cells with prominent mitosis in eccrine porocarcinoma (22).</title>
          </caption>
          <graphic xlink:href="images/image10.jpg" mime-subtype="jpg"/>
        </fig>
        <fig id="idm1842309436">
          <label>Figure 11.</label>
          <caption>
            <title> Eccrine porocarcinoma                     displaying cords and strands of atypical epithelial cells with glandular                arrangements (23).</title>
          </caption>
          <graphic xlink:href="images/image11.jpg" mime-subtype="jpg"/>
        </fig>
        <fig id="idm1842310588">
          <label>Figure 12.</label>
          <caption>
            <title> Immune reactivity to                cyto-keratin (CK7) in eccrine                          porocarcinoma(24).</title>
          </caption>
          <graphic xlink:href="images/image12.jpg" mime-subtype="jpg"/>
        </fig>
        <fig id="idm1842308356">
          <label>Figure 13.</label>
          <caption>
            <title> Immune reactivity to CK6 in            eccrine porocarcinoma(25).</title>
          </caption>
          <graphic xlink:href="images/image13.jpg" mime-subtype="jpg"/>
        </fig>
        <p>Following proliferation and epidermal infiltration, the  tumefaction can invade papillary and reticular dermis. Implication of dermal lymphatic vessels ensures  tumour dissemination to regional  lymph nodes (20%) or isolated solid organs (10%) or demonstrable localized  tumour reoccurrence(20%) <xref ref-type="bibr" rid="ridm1842118460">2</xref><xref ref-type="bibr" rid="ridm1841973484">4</xref>.                                                                     </p>
        <p>Eccrine porocarcinoma manifests lymph node invasion with capsular disruption and focal  infiltration of  surgical margins. Nodules upon the cutaneous surfaces  delineate metastasis within the dermis and subcutaneous fat  with extensive lymphatic and vascular permeation <xref ref-type="bibr" rid="ridm1841949716">7</xref><xref ref-type="bibr" rid="ridm1841941940">8</xref>.                                                                                                          </p>
        <p>Histological subtypes of eccrine porocarcinoma include</p>
        <p>Pushing variant –polypoid lesions with a well defined inferior tumour  margin.                                                                                                          </p>
        <p>Infiltrative variant –Indistinct inferior border of the neoplasm with tumour cell aggregates  infiltrating the dermis and/or hypodermis.</p>
        <p>Pagetoid variant- Intra-epidermal dissemination of tumour cells besides the delineation of primary neoplasm - recapitulating Paget’s disease.                                     </p>
        <p>Tumour nodules can appear  horizontally within the epidermis with peripheral  extension, invasion of underlying dermis  or subcutaneous adipose tissue along with  metastasis to internal  organs and viscera <xref ref-type="bibr" rid="ridm1841949716">7</xref><xref ref-type="bibr" rid="ridm1841941940">8</xref>.                                                                                        </p>
      </sec>
      <sec id="idm1849625236">
        <title>Immune Histochemical Evaluation</title>
        <p>Eccrine porocarcinoma is immune reactive to carcino-embryonic antigen (CEA) and cyto-keratins 6  and 7(CK6,7),  epithelial membrane antigen (EMA) and non reactive to  S-100 protein.  Reactivity to cyto-keratin 20 (CK20) assists  the diagnosis in  instances with indeterminate histology.  Immune reactive   p63, CK5 , weak P40   and non reactive GATA3 are additionally elucidated by the tumour <xref ref-type="bibr" rid="ridm1842118460">2</xref><xref ref-type="bibr" rid="ridm1842222492">3</xref><xref ref-type="bibr" rid="ridm1841973484">4</xref>.                                                                                                    </p>
      </sec>
      <sec id="idm1849624084">
        <title>Differential Diagnosis</title>
        <p>Nodules of eccrine porocarcinoma  located on extremities necessitate a segregation from entities such as seborrheic keratosis, pyogenic granuloma, amelanotic melanoma, squamous cell carcinoma, basal cell carcinoma or verruca vulgaris.                                                                         </p>
        <p>Tumour cell aggregates infiltrating the epidermis require a demarcation  from conditions such as hidroacanthoma simplex, Bowen’s disease or seborrheic keratosis <xref ref-type="bibr" rid="ridm1841949716">7</xref><xref ref-type="bibr" rid="ridm1841941940">8</xref>.                                                                                            </p>
        <p>Scalp lesions require a differentiation from  conditions such as  cylindroma, eccrine poroma, sebaceous adenoma, sebaceous carcinoma, pilar tumour  and metastatic carcinoma.                                                                                   </p>
        <p>Additionally, a distinction  is required from  eccrine poroma, hidradenoma,  hidroadenocarcinoma,  squamous cell carcinoma and basal cell carcinoma in instances  with  extensive  dermal infiltration <xref ref-type="bibr" rid="ridm1841941940">8</xref><xref ref-type="bibr" rid="ridm1841940284">9</xref>.                                                                                                   </p>
        <p>Eccrine porocarcinoma necessitates a differentiation from conditions such as</p>
        <p>Porocarcinoma </p>
        <p>Basal Cell Carcinoma</p>
        <p>Seborrheic Keratosis (clinical differentiation) </p>
        <p>Pyogenic granuloma (clinical differentiation) </p>
        <p>Acrochordon (clinical differentiation)                                                           </p>
        <p>Amelanotic melanoma (clinical differentiation)                                                                                                      </p>
        <p>Verrucae                                                                                                  </p>
        <p>Hidradenoma                                                                                                                                                                  </p>
        <p>Hidroadenocarcinoma                                                                                  </p>
        <p>Bowen’s disease (squamous cell carcinoma in situ)                                      </p>
        <p>Paget’s disease                                                                                               </p>
        <p>Squamous cell  carcinoma                                                                    </p>
        <p>Metastasis (pulmonary carcinoma, adjuvant malignancy)</p>
        <p>Infiltrating  duct carcinoma breast</p>
        <p>With specimens obtained from superficial  and shave biopsies, it can be challenging to differentiate eccrine poroma  from non invasive (in situ) eccrine porocarcinoma or pushing variant of eccrine porocarcinoma. However, eccrine poroma lacks attributes such as dermal invasion, marked  cytological atypia and necrosis <xref ref-type="bibr" rid="ridm1841941940">8</xref><xref ref-type="bibr" rid="ridm1841940284">9</xref>.                                                         </p>
        <p>Eccrine porocarcinoma can be differentiated  from infiltrating basal cell carcinoma due to  the demonstration of intercellular bridges, absence of peripheral palisade and tumour retraction artefact <xref ref-type="bibr" rid="ridm1842118460">2</xref><xref ref-type="bibr" rid="ridm1842222492">3</xref>.                                 </p>
        <p>Squamoid eccrine porocarcinoma can be distinguished from squamous cell carcinoma which lacks duct-like articulations and intra-cytoplasmic duct lumina.  Aforesaid features can be discerned  with adequate immune reactivity to EMA and CEA in eccrine porocarcinoma.                                                                    </p>
        <p>Infiltrating primary  duct carcinoma of the breast  necessitates a distinction from eccrine porocarcinoma appearing within breast tissue or  axillary lymph nodes. Misdiagnosis can occur in an estimated 30% instances. </p>
        <p>Eccrine porocarcinoma  depicts contiguity of the tumour to superficial  epidermis with  ductal eccrine differentiation. Cogent immune reactions  with non reactive cyto-keratin (CK7), hormone receptors (oestrogen or progesterone)  or GATA3 enunciates an absence of primary breast carcinoma <xref ref-type="bibr" rid="ridm1842222492">3</xref><xref ref-type="bibr" rid="ridm1841973484">4</xref>.                                                                                </p>
        <p>Eccrine porocarcinoma  is diffusely immune reactive to p63 and cyto-keratin 5 (CK5), in contrast to a metastatic carcinoma of the skin  which is  non reactive p63 or CK5 <xref ref-type="bibr" rid="ridm1841940284">9</xref><xref ref-type="bibr" rid="ridm1841919204">10</xref>.                                                                                                                         </p>
      </sec>
      <sec id="idm1849601796">
        <title>Investigative Assay</title>
        <p>A comprehensive medical history with incidents  of  exposure to  toxins and carcinogens is mandated. Extensive evaluation of the implicated skin and adjacent lymph nodes is required. Ultrasound  can be performed for analysing  enlarged lymph nodes. Fine needle aspiration cytology can depict a primary or metastatic carcinoma consistent with eccrine porocarcinoma.                                                                               Computerized tomography  of the pelvis, abdomen and thorax  can be  performed and exhibits a poorly demarcated, variable, dense,  soft tissue lesion devoid of erosion of the underlying  bone <xref ref-type="bibr" rid="ridm1841940284">9</xref><xref ref-type="bibr" rid="ridm1841919204">10</xref>.                                                                               </p>
        <p>Computerized tomography can  also disclose an enlarged tumour mass  with infiltration of adjoining soft  tissue and incriminated regional  lymph nodes.                                                                                                            Fluoro-deoxy glucose (FDG PET CT) positron emission computerized tomography of  localized tumour aggregates depict intense FDG avid tumour nodules or infiltrated lymph nodes.                                                           </p>
        <p>FDG PET CT scans employed for elucidating  a reoccurrence in  porocarcinoma  can display  multiple FDG avid regions on the cutaneous surface and regional lymph nodes.  Repetitive FDG PET CT scans  can  expose additional lesions confined to the skin, bone, lungs or lymph nodes <xref ref-type="bibr" rid="ridm1841940284">9</xref><xref ref-type="bibr" rid="ridm1841919204">10</xref>.                                                                                                             </p>
        <p>Primary tumour and subsequent metastasis exhibits  an enhanced glucose metabolism which aids appropriate detection <xref ref-type="bibr" rid="ridm1841919204">10</xref><xref ref-type="bibr" rid="ridm1841917044">11</xref>.                                                                </p>
        <p>Positron emission tomography ( PET  CT) can be utilized to similarly delineate tumour nodules or incriminated lymph nodes. However, a close monitoring is advised as PET CT demonstrates a reduced sensitivity to miniature  lesions. Comprehensive bone scan can be ordered to detect adjuvant lesions or exclude bone metastasis.  Magnetic resonance imaging is  employed to indicate additional locations of the neoplasm. Magnetic resonance imaging  delineates the target tumour volume with  identification of adjoining neural / vascular structures <xref ref-type="bibr" rid="ridm1841919204">10</xref><xref ref-type="bibr" rid="ridm1841917044">11</xref>.                                                           </p>
      </sec>
      <sec id="idm1849600788">
        <title>Prognostic Determinants</title>
        <p>Attributes of eccrine porocarcinoma associated with inferior prognosis include mitotic activity and  tumour thickness besides  lymphatic and vascular invasion. Neoplasm displaying an invasive tumour border instead of a pushing inferior tumour margin is associated with enhanced percentage of  tumour reoccurrence.                                                                                                       </p>
        <p>Tumour reappearance occurs in an estimated one third (35%) instances and is commonly elucidated  with pagetoid or infiltrative histological  subcategories. Pushing subtype seldom relapses. Emergence of infiltrative tumour perimeter appears to be  predictive of localized tumour  reoccurrence <xref ref-type="bibr" rid="ridm1841973484">4</xref><xref ref-type="bibr" rid="ridm1841969308">5</xref>.                                                                                               </p>
        <p>Extent of  tumour resection margin (≥2 centimetres) or (&lt; 2 centimetres) or adoption of narrow resection margin  with  modified Moh’s micrographic surgery (MMS) may not influence prognostic outcomes, irrespective  of  the histological subtype encountered.                                         Inferior prognostic  outcome  with frequent mortality is indicated with  aspects such as mitotic figures beyond &gt; 14 mitosis /high power field, lymphatic and vascular invasion with lymph node metastasis, depth of  tumour invasion exceeding  &gt; 7millimteres and infiltrative tumour perimeter <xref ref-type="bibr" rid="ridm1842118460">2</xref><xref ref-type="bibr" rid="ridm1841973484">4</xref>.                                                                                                             </p>
        <p>Multi-nodular or ulcerative, rapidly enhancing  lesions can reoccur subsequent to  adoption of a  wide surgical  excision. Consequently, an unfavourable  prognosis and mortality ensues due to malignant  metastasis. Aforesaid instances are  unresponsive to chemotherapy or radiotherapy. A mortality rate of up to 80% can be encountered in invasive, ulcerated or             multi-nodular tumours <xref ref-type="bibr" rid="ridm1841940284">9</xref><xref ref-type="bibr" rid="ridm1841919204">10</xref>.                                                                                                                             </p>
      </sec>
      <sec id="idm1849600428">
        <title>Therapeutic Options</title>
        <p>Benign poroma necessitates a therapeutic  surgical extermination as an estimated  20% instances can transform into infiltrative, malignant neoplasm.  Simple surgical  excision ensures  a complete alleviation of the condition  for miniature lesions. Alternatively,  Moh’s micrographic surgery can be employed for enlarged  or deep-seated  lesions. Superficial lesions can be managed by a fulguration , cautery, surgical elimination or electro-cauterization.                                                                                             </p>
        <p>Non metastatic eccrine porocarcinoma  is appropriately alleviated  by a surgical eradication  with a broad tumour perimeter <xref ref-type="bibr" rid="ridm1841917044">11</xref><xref ref-type="bibr" rid="ridm1841912724">12</xref>.                                                   </p>
        <p>Adoption of surgical excision with a wide margin in early eccrine porocarcinoma  enunciates a proportionate cure rate of 70% of 80%.     Comprehensive surgical resection of the tumour is a  preferred treatment modality. Surgical  extermination with removal of a tumour perimeter of one centimetre is advocated. Skin grafting can be employed to repair the surgical defect <xref ref-type="bibr" rid="ridm1841912724">12</xref><xref ref-type="bibr" rid="ridm1841870316">13</xref>.                                                                                             </p>
        <p>Singular surgical elimination  is curative in a majority (70%) instances. Aggressive, localized  surgical eradication with a tumour free surgical perimeter is optimal. Infiltrated tumour margins also mandate a wide surgical extermination on account of extensive  regional  metastasis.                                                                                                       </p>
        <p>Surgical dissection can be challenging on account of intense  adherence of the  tumefaction  to circumscribing  soft tissue and vascular configurations.                                                                           Complications such as post operative  haemorrhage  and infection  mandate reparative intervention.  Suitable surgical elimination  of the primary lesion exemplifies a proportionate alleviation of beyond  &gt; 80%  with a  reoccurrence of beneath  &lt; 20% <xref ref-type="bibr" rid="ridm1841917044">11</xref><xref ref-type="bibr" rid="ridm1841870316">13</xref>.                                                                          </p>
        <p>Moh’s micrographic surgery also provides a cogent therapeutic  option. Minimally aggressive pushing subtype of eccrine porocarcinoma can be managed with surgical resection of a narrow margin of uninvolved tissue. Modified Moh’s micrographic surgery can be adapted  for eliminating  infiltrative or pagetoid subtype of eccrine porocarcinoma <xref ref-type="bibr" rid="ridm1842222492">3</xref><xref ref-type="bibr" rid="ridm1841973484">4</xref>.                                                                                                                                                 </p>
        <p>Regional lymph nodes require evaluation as porocarcinoma depicts a predilection for invasion of  dermal lymphatic vessels with a consequent   tumour burden within the regional lymph nodes  in an estimated 20% instances. Incriminated regional lymph nodes  necessitate an appropriately expansive  lymph node dissection.   Prophylactic  and extensive dissection of regional lymph nodes is advocated in approximately 20% instances with  inferior  prognostic outcomes which are  characteristically delineated by  lymphatic or vascular invasion, infiltrating or pagetoid tumour variant  or an enhanced grade of lesions cogitated with localized tumour reoccurrence <xref ref-type="bibr" rid="ridm1841941940">8</xref><xref ref-type="bibr" rid="ridm1841940284">9</xref>.                                                       </p>
        <p>Adjuvant radiation therapy  is an additional modality which is recommended in subjects with infiltration of surgical  perimeter. Unfavourable prognostic parameters  such as focal infiltration of resection margin, prominent lymphatic and vascular invasion, lymph node incrimination and capsular disruption  can mandate the employment of  adjuvant radiotherapy.                                                </p>
        <p>Chemotherapy is a cogent modality for managing metastatic lesions. Eccrine porocarcinoma depicts loco-regional tumour reappearance in an estimated 20% subjects  with  visceral or bone metastasis in approximately 10% instances following adequate surgical eradication of primary                   tumefaction <xref ref-type="bibr" rid="ridm1841912724">12</xref><xref ref-type="bibr" rid="ridm1841870316">13</xref>.                                                                                               </p>
        <p>Nevertheless,  surgical  re-excision remains the therapeutic paradigm in locally or regionally metastatic eccrine porocarcinoma. Comprehensive  radiotherapy and chemotherapy  can also be  considered as an option.                                                                                                </p>
        <p>Individual survival can be enhanced in metastatic disease with the employment of palliative chemotherapy  and/or radiotherapy. Systemic chemotherapy with tamoxifen or docetaxel  is an efficacious alternative  to surgery <xref ref-type="bibr" rid="ridm1841912724">12</xref><xref ref-type="bibr" rid="ridm1841870316">13</xref>.                                                                                                                                                                                                                                        </p>
      </sec>
    </sec>
  </body>
  <back>
    <ref-list>
      <ref id="ridm1842115508">
        <label>1.</label>
        <mixed-citation xlink:type="simple" publication-type="journal">
          <name>
            <surname>Pinkus</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Mehregan</surname>
            <given-names>A H</given-names>
          </name>
          <article-title>Epidermotropic eccrine carcinoma: a case combining features of eccrine poroma and Paget’s dermatosis”</article-title>
          <date>
            <year>1963</year>
          </date>
          <source>Arch Dermatol</source>
          <volume>88</volume>
          <fpage>597</fpage>
          <lpage>606</lpage>
        </mixed-citation>
      </ref>
      <ref id="ridm1842118460">
        <label>2.</label>
        <mixed-citation xlink:type="simple" publication-type="journal">
          <name>
            <surname>Monten</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Berwouts</surname>
            <given-names>J</given-names>
          </name>
          <article-title>A case of eccrine porocarcinoma located in the breast – the pitfalls reviewed “ iMedPub Journals –Medical Case Reports</article-title>
          <date>
            <year>2018</year>
          </date>
          <volume>4</volume>
          <issue>1</issue>
          <fpage>004</fpage>
          <lpage>18</lpage>
        </mixed-citation>
      </ref>
      <ref id="ridm1842222492">
        <label>3.</label>
        <mixed-citation xlink:type="simple" publication-type="journal">
          <name>
            <surname>Inamdar</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Naik</surname>
            <given-names>R</given-names>
          </name>
          <article-title>Eccrine porocarcinoma of scalp : an unusual malignancy of the sweat glands” Clinic in Surgery</article-title>
          <date>
            <year>2018</year>
          </date>
          <volume>3</volume>
          <fpage>1865</fpage>
        </mixed-citation>
      </ref>
      <ref id="ridm1841973484">
        <label>4.</label>
        <mixed-citation xlink:type="simple" publication-type="journal">
          <name>
            <surname>Seo</surname>
            <given-names>B F</given-names>
          </name>
          <name>
            <surname>Choi</surname>
            <given-names>H J</given-names>
          </name>
          <article-title>Eccrine porocarcinoma on the cheek”Archives of Craniofacial Surgery</article-title>
          <date>
            <year>2018</year>
          </date>
          <volume>20</volume>
          <issue>1</issue>
          <fpage>48</fpage>
          <lpage>50</lpage>
        </mixed-citation>
      </ref>
      <ref id="ridm1841969308">
        <label>5.</label>
        <mixed-citation xlink:type="simple" publication-type="journal">
          <name>
            <surname>Choi</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Kim</surname>
            <given-names>Y J</given-names>
          </name>
          <article-title>A rare case of abdominal porocarcinoma”</article-title>
          <date>
            <year>2014</year>
          </date>
          <source>Arch Plast Surg</source>
          <volume>41</volume>
          <fpage>93</fpage>
          <lpage>95</lpage>
        </mixed-citation>
      </ref>
      <ref id="ridm1841952812">
        <label>6.</label>
        <mixed-citation xlink:type="simple" publication-type="journal">
          <name>
            <surname>Brown</surname>
            <given-names>CW Jr</given-names>
          </name>
          <name>
            <surname>Dy</surname>
            <given-names>L C</given-names>
          </name>
          <date>
            <year>2008</year>
          </date>
          <source>Eccrine porocarcinoma” Dermatol Ther</source>
          <volume>21</volume>
          <fpage>433</fpage>
          <lpage>8</lpage>
        </mixed-citation>
      </ref>
      <ref id="ridm1841949716">
        <label>7.</label>
        <mixed-citation xlink:type="simple" publication-type="journal">
          <name>
            <surname>Chang</surname>
            <given-names>O</given-names>
          </name>
          <name>
            <surname>Elnawani</surname>
            <given-names>A</given-names>
          </name>
          <article-title>Eccrine porocarcinoma of the lower extremity : a case report and review of literature”</article-title>
          <date>
            <year>2011</year>
          </date>
          <source>World J Surg Oncol</source>
          <volume>9</volume>
          <fpage>94</fpage>
        </mixed-citation>
      </ref>
      <ref id="ridm1841941940">
        <label>8.</label>
        <mixed-citation xlink:type="simple" publication-type="journal">
          <name>
            <surname>Golemi</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Hanspeter</surname>
            <given-names>E</given-names>
          </name>
          <article-title>FDG/PET CT in malignant eccrine porocarcinoma arising in a pre-existing poroma”</article-title>
          <date>
            <year>2014</year>
          </date>
          <source>Clin Nuc Med:</source>
          <volume>39</volume>
          <fpage>456</fpage>
          <lpage>458</lpage>
        </mixed-citation>
      </ref>
      <ref id="ridm1841940284">
        <label>9.</label>
        <mixed-citation xlink:type="simple" publication-type="journal">
          <name>
            <surname>Skowron</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Poulhalon</surname>
            <given-names>N</given-names>
          </name>
          <article-title>Primary eccrine porocarcinoma : a clinicopathological study of 50 cases”</article-title>
          <date>
            <year>2014</year>
          </date>
          <source>Ann Dermatol Venereol:</source>
          <volume>141</volume>
          <fpage>258</fpage>
          <lpage>264</lpage>
        </mixed-citation>
      </ref>
      <ref id="ridm1841919204">
        <label>10.</label>
        <mixed-citation xlink:type="simple" publication-type="journal">
          <name>
            <surname>Reira</surname>
            <given-names>Leal L</given-names>
          </name>
          <name>
            <surname>Guevara-Gutierrez</surname>
            <given-names/>
          </name>
          <article-title>Eccrine porocarcinoma: epidemiologic and histopathologic characteristics”</article-title>
          <date>
            <year>2015</year>
          </date>
          <source>Int J Dermatol</source>
          <volume>54</volume>
          <fpage>580</fpage>
          <lpage>586</lpage>
        </mixed-citation>
      </ref>
      <ref id="ridm1841917044">
        <label>11.</label>
        <mixed-citation xlink:type="simple" publication-type="journal">
          <name>
            <surname>Aaribi</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Mohataram</surname>
            <given-names>A</given-names>
          </name>
          <article-title>Successful management of eccrine porocarcinoma “ Case Rep Oncol Med:</article-title>
          <date>
            <year>2013</year>
          </date>
          <fpage>282536</fpage>
        </mixed-citation>
      </ref>
      <ref id="ridm1841912724">
        <label>12.</label>
        <mixed-citation xlink:type="simple" publication-type="journal">
          <name>
            <surname>Robson</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Greene</surname>
            <given-names>J</given-names>
          </name>
          <article-title>Eccrine Porocarcinoma ( malignant eccrine poroma): a clinicopathologic study of 69 cases</article-title>
          <date>
            <year>2001</year>
          </date>
          <source>Am J Surg Pathol</source>
          <volume>25</volume>
          <fpage>710</fpage>
          <lpage>20</lpage>
        </mixed-citation>
      </ref>
      <ref id="ridm1841870316">
        <label>13.</label>
        <mixed-citation xlink:type="simple" publication-type="journal">
          <name>
            <surname>Sharathkumar</surname>
            <given-names>H K</given-names>
          </name>
          <name>
            <surname>Hemlatha</surname>
            <given-names>A L</given-names>
          </name>
          <article-title>Eccrine porocarcinoma : a case report</article-title>
          <date>
            <year>2001</year>
          </date>
          <source>J Clin Diag Res</source>
          <volume>7</volume>
          <issue>12</issue>
          <fpage>2966</fpage>
          <lpage>7</lpage>
        </mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
